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Abstract 
 Progestogens share one common effect: the ability to convert proliferative endometrium to its secretory 
form. In contrast, their biological activity is varied, depending on the chemical structure, pharmacokinetics, 
receptor affinity and different potency of action. Progestogens are widely used in the treatment of menstru-
al cycle disturbances, various gynaecological conditions, contraception and menopausal hormone therapy.  
The administration of progestogen in menopausal hormone therapy is essential in women with an intact uterus 
to protect against endometrial hyperplasia and cancer. Progestogen selection should be based on the charac-
teristics available for each progestogen type, relying on the assessment of relative potency of action in experi-
mental models and animal models, and on the indirect knowledge brought by studies of the clinical use of dif-
ferent progestogen formulations. The choice of progestogen should involve the conscious use of knowledge of 
its benefits, with a focus on minimizing potential side effects. Unfortunately, there are no direct clinical studies 
comparing the metabolic effects of different progestogens.
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Introduction
Progestogens are substances exhibiting a  proge-
stagenic effect, i.e. inducing secretory transformation 
in the endometrium which was previously affected by 
oestrogens, thus mimicking the activity of endogenous 
progesterone in the luteal phase of the menstrual cycle.
Although progestogens are currently widely used in 
gynaecology, and not uncommonly also in obstetrics, 
the body of knowledge about progestogens, as well as 
terminology, appears rather chaotic and insufficiently 
systematized. A variety of interchangeable names are 
used, including progestagen, progestogen, gestagen, 
gestogen and progestin. According to the recommenda-
tions issued by the North American Menopause Society, 
the present study uses the term “progestogen”, by anal-
ogy to other classes of hormonal drugs, e.g. oestrogens 
or androgens, and the term “progestin” which refers to 
synthetic progestogens, i.e. excludes progesterone [1].
Progestogens produce their physiological and bio-
logical effects via the progesterone receptors A (PR-A) 
and B (PR-B). Both of them are nuclear receptors, the 
difference being that PR-B has an additional amino acid 
sequence at the terminal NH
2 group. In experimental 
conditions progestins bind to both progesterone recep-
tors with a  high, though varied, affinity. The expres-
sion of genes by PR is regulated through different, also 
extragenomic, mechanisms. In addition, progestogens 
modulate gene transcription due to their affinity to 
other steroid receptors: androgen receptor (AR), gluco-
corticoid receptor (GR) and mineralocorticoid receptor 
(MR). Studies of affinity, as well as the type and relative 
potency of action of different progestogens, are based 
on experiments conducted on animal models and hu-
man cell lines and tissues. However, biological response 
may differ depending on the achieved concentration, 
duration of action and effects caused by adjacent struc-
tures and tissues.
The biological activity of progestogens is varied and 
influenced by their chemical structure, pharmacokinet-
ics and potency of action. The metabolism of progesto-
gens is still poorly understood, however it is definitely 
determined by the route of administration, among 
other factors. Following oral administration, progesto-
gens are partially metabolized by enzymes produced 
by bacteria living in the stomach and small intestine, 
and during the process of mucosal absorption. After 
reaching the liver, the “first passage effect” is observed, 
i.e. an intensive metabolic process involving primarily 
cytochrome P450 enzymes. The liver is the main site 
for the metabolism of progestogens also when they are 
administered via other routes. Some progestins (e.g. 
desogestrel or norgestimate) are pro-drugs, i.e. become 
active only through the formation of metabolites. Final-
ly, due to the activity of sulphatases, some conjugated 
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metabolites may be subject to secondary absorption in 
the intestine and repeated activity.
Indications for progestogen treatment in the pre-
menopausal period are menstrual disorders affecting 
both the frequency of the menstrual cycle (polymenor-
rhea, oligomenorrhea) and the severity of bleeding (hy-
pomenorrhea, hypermenorrhea), and heavy prolonged 
bleeding without an underlying organic condition. Some 
progestins are used as contraceptives, either alone or in 
conjunction with oestrogen.
The only indication for progestogen use during men-
opausal hormone therapy (MHT) is to protect the uter-
us from endometrial hyperplasia and thus eliminate the 
risk of endometrial cancer which would be induced by 
the prolonged use of unbalanced oestrogens [2].
The selection of progestogens for therapy should be 
based on the available knowledge of their mechanisms 
of action and differences between them. The bioavail-
ability of different progestogens depends on multiple 
factors including the route of administration, metabo-
lism, protein-binding strength and additional binding to 
other steroid receptors (AR, GR, MR) and action triggered 
via this pathway. Progestogens vary in their activity (not 
only as a result of differences in chemical structure but 
also in the strength of binding to different receptors), 
intracellular activity and often also biological and clini-
cal effects. What is more, they may exhibit differences in 
the safety profile and the risk of interactions with other 
drugs used concomitantly in combination therapy. 
Another important factor affecting the pharmacoki-
netics of all drugs, progestogens included, is the aging 
process. Changes arise as a result of deteriorated liver 
function (impairment of the cytochrome P450 system, 
modified activity of P-glycoprotein) and kidney func-
tion, but also reduced cardiac output and decline in 
lung function. Another factor which merits considera-
tion is the reduction of conjugation processes occurring 
in the liver, which is important for the metabolism and 
clearance of certain progestogens. It is usually accom-
panied by changes in body weight and composition, 
and aging-related decreased muscle mass. The factors 
should be taken into account in differentiating treat-
ment and drug doses between perimenopausal and el-
derly women (over 65 years of age). 
Progesterone
Progesterone (P) triggers secretory transformation 
of the endometrium during the proliferative phase 
induced by oestradiol. It is critical for embryo implan-
tation and maintenance of pregnancy. In addition to 
regulating the reproductive system, progesterone has 
a crucial effect on the mammary glands and the central 
nervous system.
It demonstrates a  strong progestagenic and anti-
oestrogenic activity in the endometrium and cervix, 
and exerts marked antimineralocorticoid and antian-
drogenic effects as a result of competitive inhibition of 
5α-reductase activity in the skin.
After oral administration P is rapidly metabolized in 
the gastrointestinal tract and liver, producing up to 30 
metabolites. Among them, 5α- and 5β-pregnanolones 
have a  sedative effect through binding to the GABAA 
(gamma-aminobutyric acid type A) receptor. Other im-
portant metabolites include 20-dihydroprogesterone 
(25-50% of progestogen potency), 11-deoxycorticos-
terone (strong mineralocorticosteroid), 17α-hydroxy-
progesterone and the inactive end product – pregnan-
ediol. The proportions of metabolites show a very high 
degree of individual variation. Low bioavailability after 
oral administration was improved by micronization and 
then encapsulation of micronized progesterone sus-
pended in oil in gel capsules. Following oral administra-
tion of 200 mg of progesterone in this form, the maximum 
P concentration determined by RIA (radioimmunoassay) 
occurs after 4 hours and amounts to 12 ng/ml, 
the concentration of 5α-pregnanolon is 30 ng/ml and 
5β-pregnanolon – 60 ng/ml. Approximately 17% of cir-
culating P is bound with a high affinity to CBG, and 80% 
is bound with low affinity to albumins.
Oral micronized progesterone (MP) preparations are 
used in MHT at daily doses of 200-300 mg, ensuring 
sufficient protection against endometrial hyperplasia 
with a standard oestrogen dose. In sequential therapy, 
combining MP at a dose of 200 mg for 12-14 days with 
oral or transdermal oestrogen at a standard dose pre-
vents endometrial hyperplasia, causing regular with-
drawal bleeding in 60% of women and amenorrhoea 
in a part of the remaining group. MP at a  lower dose 
(100 mg) administered for 21-25 days of the cycle in 
conjunction with 150 µg of oestradiol via the transder-
mal route improved tolerance (reduced drowsiness, 
tiredness and dizziness), and increased the percentage 
of amenorrhoea. 
The intramuscular form of MP in oil (50-100 mg dai-
ly), which is still available in some countries, is mainly 
used today in in vitro fertilization programmes. Clinical 
trials are currently under way investigating an aque-
ous solution for subcutaneous administration which, at 
a dose of 25 mg, would deliver a similar effect as intra-
vaginal gel at a daily dose of 90 mg.
Intravaginal progesterone in the form of 8% gel 
(90 mg) or tablets (200 mg) is used after IVF up to 8-12 
weeks, and is approved for the prevention of premature 
birth in patients with a history of premature termina-
tion of one previous pregnancy and shortening of the 
cervical length to ≤ 25 mm. The intravaginal route of 
administration ensures higher and more stable P con-
centrations in the blood serum. After intravaginal ap-
plication of 100 mg of MP in a gel capsule, the maxi-
mum concentration of P in the blood serum (around 
5 ng/ml) was noted after 6 hours, and was maintained 
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for 24 hours. The concentration of 5α-pregnanolone 
was 3.5 ng/ml after 2 hours, and the concentration of 
5β-pregnanolone did not change [3].
A comparison of the effects of repeated administra-
tion of progesterone by the intramuscular (2 × 50 mg) 
and intravaginal (4 × 200 mg) routes reveals that the 
former route ensures a high constant concentration in 
the blood, whereas the latter causes a  tenfold higher 
concentration in the uterus. The finding points to the 
so-called uterine first pass effect following intravaginal 
administration [4].
Transdermal progesterone preparations in the form 
of a cream or gel fail to ensure an adequate P concen-
tration in the blood despite achieving a  variably high 
concentration in saliva and capillary blood tests. Con-
sequently, in one third of cases the combination with 1 
mg of oestradiol produces an inadequate endometrial 
effect: it remains in the proliferative phase or endome-
trial hyperplasia occurs [5]. It was assumed that the 
concentration of P in the blood should exceed 5 ng/ml 
in order to inhibit mitotic divisions and induce the se-
cretory transformation of the endometrium [6]. 
In some countries, 1% progesterone gel is approved 
for the treatment of premenstrual mastodynia. The 
topical administration of P in the form of a  cream or 
gel gives rise to concern because it leads to excessive 
tissue concentrations and concurrently low concentra-
tions in the blood. Such supraphysiological saturation 
of tissues and progesterone receptors with progester-
one may have an adverse effect on clinical response 
through the PR and a decrease in the ER, and cause an 
excessive formation of progesterone metabolites with 
agonist or antagonist activity [6]. New evaluated prepa-
rations of aqueous, rather than alcoholic, progesterone 
gels require in-depth clinical trials.
Attempts to use progesterone alone (without oes-
trogen) in the form of a cream at daily doses from 20 
to 60 mg to relieve vasomotor symptoms failed to im-
prove the quality of life, and the achieved results did 
not differ from the placebo effect [7]. Progesterone has 
not been found to produce clinically significant inter-
actions with other drugs. In vitro studies have shown 
that cytochrome P450 inhibitors, e.g. azole antifungal 
medications, can slow down the metabolism of pro-
gesterone. Progesterone may also increase the serum 
concentration of cyclosporine. High progesterone doses 
may transiently increase the rate of sodium and chlo-
ride excretion from the body.
Review of progestins used in menopausal 
hormone therapy which are available in 
Poland
Dienogest
Dienogest (DNG) is a  derivative of 19-nortes-
tosterone, but due to its structure it is the only pro-
gestogen which also possesses the properties of 
17α-hydroxyprogesterone. This is because instead of 
having an ethyl group at position C17, dienogest has 
a  cyanomethyl group and a double bond between C9 
and C10. In addition to a very fast absorption rate, di-
enogest exhibits a  very high bioavailability of around 
90%. It is bound to albumins in 90%, and around 
10% is in a  free form. It binds neither to SHBG, nor 
CBG. Its metabolites are inactive and rapidly excreted. 
The half-life is 10 hours. Stable concentrations are 
achieved after two days of treatment. Dienogest does 
not accumulate in the body. It demonstrates a poor af-
finity to the PR, but has a  very potent progestagenic 
effect in the endometrium, and causes endometrial at-
rophy after prolonged use. It shows antagonist activity 
by binding to the AR, and hence produces an antiandro-
genic action equivalent to ca. 40% of the effect induced 
by cyproterone acetate. Dienogest does not interact 
with the GR, MR or ER.
In vivo, it has a powerful progestagenic and moder-
ate antigonadotropic activity, without any androgenic, 
glucocorticoid or mineralocorticoid effects. A  dose of 
2 mg inhibits the growth of ovarian follicles at 10 mm 
and maintains the concentration of progesterone at 
a low level, but has a weak inhibitory effect on FSH and 
LH. Consequently, dienogest is believed to have a weak 
central antigonadotropic action, but a potent direct pe-
ripheral ovulation-inhibiting effect [8].
Dienogest in the form of 2 mg tablets is used in the 
treatment of endometriosis. It has been available for 
many years in the same dose in a combined oral con-
traceptive pill (COCP) in conjunction with 30 µg of ethi-
nyloestradiol in cases where an additional indication is 
the treatment of moderate acne. Dienogest combined 
with oestradiol valerate in the first four-phasic COCP 
has an additional indication for the treatment of exces-
sively heavy or prolonged menstrual bleeding.
In MHT, the same dose can be administered with 
1 mg or 2 mg of oestradiol valerate.
Even high doses of the drug, more than ten times 
higher than the commonly used doses, do not exert an 
adverse effect on the lipid profile, coagulation system 
or carbohydrate metabolism. Dienogest is metabolized 
chiefly via the CYP3A4 isoenzyme. Drugs inhibiting 
the isoenzyme, including azole antifungals (ketocona-
zole, fluconazole, itraconazole), cimetidine, verapamil, 
macrolides (e.g. erythromycin, clarithromycin, roxyth-
romycin), diltiazem, protease inhibitors (e.g. ritonavir, 
saquinavir, indinavir, nelfinavir), antidepressants (e.g. 
fluvoxamine, fluoxetin) and grapefruit juice, may de-
crease the clearance rate of dienogest and trigger ad-
verse reactions. Drugs inducing the isoenzyme, such 
as phenytoin, barbiturates, primidone, carbamazepin, 
rifampicin, oxcarbazepine, topiramate, felbamate, gri-
seofulvin, nevirapine and products containing St. John’s 
wort (Hypericum perforatum), may increase the clear-
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ance rate of sex hormones and diminish the activity of 
dienogest, potentially causing changes in the uterine 
bleeding profile.
Drospirenone
Drospirenone (DRSP) is a derivative of 17α-spirono-
lactone. It is rapidly absorbed after oral administration, 
and reaches its maximum concentration in the blood 
within 1-2 hours. The bioavailability of DRSP is 76%, and 
its half-life equals 25-33 hours. It is completely excreted 
within 10 days. Circulating DRSP is albumin-bound. It 
has no active metabolites. Its affinity to the mineralo-
corticoid receptor is estimated to be five times more 
potent than aldosterone. Consequently, it enhances 
the secretion of sodium and the retention of potassium 
with a  dose-dependent intensity, approximately 8-10 
times more potently than spironolactone. Drospirenone 
exhibits a more powerful antimineralcorticoid activity 
than progesterone. Through binding to the AR, it has 
an antiandrogenic effect whose relative potency corre-
sponds to 30% of the standard (cyproterone acetate).
It is used in a  combined oral contraceptive pill at 
a dose of 3 mg in conjunction with 20 or 30 µg of ethi-
nyloestradiol.
Drospirenone has also found application in continu-
ous low-dose MHT: 1 mg of oestradiol is combined with 
2 mg of DRSP ensuring endometrial atrophy through 
the apoptotic activity on the glandular epithelium. 
The antimineralcorticosteroid action reduces salt reten-
tion and causes a statistically significant mild decline 
in systolic and diastolic blood pressure compared to 
placebo. DRSP + E
2 is also claimed to have a favourable 
effect on the sense of smell [9]. Drospirenone may af-
fect the renin activity of plasma. It needs to be noted 
that patients taking drospirenone and angiotensin-
converting-enzyme inhibitors, AT
1 receptor antagonists 
and spironolactone may experience interactions mani-
fested as an increase in blood serum concentration of 
potassium. Consequently, patients require potassium 
level monitoring during the initial period of treatment.
Dydrogesterone
Dydrogesterone is a retroprogesterone as a stereoi-
somer of progesterone with an additional double bind-
ing between C6 and C7. As a consequence, dydroges-
terone differs from oral progesterone in its metabolism 
and action. Despite having a  slightly lower affinity of 
binding to the PR, dydrogesterone exhibits better bio-
availability, and doses necessary to achieve secretory 
transformation of the endometrium are 10-20 times 
lower. It has a highly selective action. It demonstrates 
no antigonadotropic activity and has no inhibitory ef-
fect on the ovulation. Also, dydrogesterone has no oes-
trogenic, androgenic, antiandrogenic and glucocorticoid 
activity. It produces a weak antimineralcorticoid effect, 
but has no thermogenic properties. Dydrogesterone is 
highly active after oral administration. It is very rapidly 
absorbed and then metabolized, chiefly to 20α-hydroxy 
derivatives including 20α-dihydrodydrogesterone (DHD) 
which achieves the highest concentration after ca. 
90 minutes and has a similar profile of action. The mean 
half-life of dydrogesterone is 5-7 hours, and DHD is 14-
17 hours. It is completely excreted within 72 hours. The 
equilibrium of concentrations is achieved after three 
days of treatment.
Dydrogesterone is used in all cases of deficiency of 
endogenous progesterone, but it does not have its ther-
mogenic effect. At doses of 10-30 mg, dydrogesterone 
is used in the treatment of dysmenorrhoea, secondary 
amenorrhoea, irregular menstrual cycles, premenstrual 
syndrome, threatened or recurrent miscarriage, abnor-
mal uterine bleeding and pain in endometriosis.
In sequential MHT, it has found application in two 
preparations in a  10 mg course for 14 days in con-
junction with oestradiol in 1 mg or 2 mg doses, and 
in continuous therapy in two consecutive regimens at 
5 mg or 2.5 mg in conjunction with 1 mg or 0.5 mg of 
oestradiol, respectively. Such diversity of preparations 
makes it possible to adjust the type of MHT to the se-
verity of menopausal symptoms and women’s age. All 
of them ensure a statistically significant improvement 
in vasomotor symptoms and other observed menopau-
sal symptoms in relation to the baseline – the onset of 
therapy – and comparable preparations [10]. There are 
no reports of clinically significant interactions of dydro-
gesterone with other concurrently taken drugs.
Levonorgestrel and norgestrel
Levonorgestrel (LNG) is a potent progestogen which 
does not have any glucocorticoid and antimineralcorti-
coid activity but displays a certain level of androgenic 
activity. DL-norgestrel is a mixture of equal parts of LNG 
and inactive D-norgestrel, hence the hormonal activity 
of 0.5 mg of norgestrel is equivalent to 0.25 mg of LNG.
The bioavailability of LNG after oral administration 
reaches 95%. In the blood, it is bound in 50% to albu-
mins and in 48% to SHBG. The half-life is 24 hours and 
one hour, respectively. Due to its androgenic activity, 
it can lower the concentration of SHBG, unless (as in 
COCP) it is bound to a potent oestrogen – ethinyloestra-
diol (EE), cumulatively leading to the maintenance of 
the SHBG level. Levonorgestrel at a dose of 300 µg used 
in conjunction with 2 mg of oestradiol in postmenopau-
sal women makes it possible to achieve the maximum 
concentration of 6.2 ng/ml after an hour, with a half-life 
of 32 hours. 
The sequential transdermal release of 10 µg of 
LNG in the second phase of the menstrual cycle and 
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50 µg of oestradiol daily from a weekly patch ensures 
the mean blood concentration of LNG at a level of 120 
pg/ml, and oestradiol at 30 pg/ml. Other dose options 
(15 µg of LNG and 75 µg E2, and 20 µg of LNG and 
100 µg of E2 daily) also guarantee endometrial safety 
[11]. Continuous transdermal MHT, combining the re-
lease of 45 µg of E2 with various doses of LNG (15-30-
45 µg) daily, has been shown to protect the endometri-
um from hyperplasia, but also cause irregular bleeding 
in a high percentage of cases (29-37%).
The levonorgestrel intrauterine system LNG-IUS 20 
is approved in some countries for endometrial protec-
tion during MHT. The vertical arm of the T-shaped sys-
tem is provided with a  reservoir containing 52 mg of 
LNG. The initial release is 20 µg, and the mean release 
is 12 µg of LNG daily for a period of 5 years. The LNG 
concentration in the blood is 0.5 ng/ml during the first 
year of use. After an initial couple of months of irregu-
lar bleeding, continuous LNG release leads to endome-
trial atrophy and stoppage of bleeding. In conjunction 
with E
2 administered orally at a daily dose of 2 mg or 
E2 released transdermally at a dose of 50 µg, it offers 
effective endometrial protection and halts bleeding in 
two thirds of postmenopausal women. A new smaller 
version of the system containing 13.5 mg of LNG and 
releasing initially 14 µg of LNG daily and 6 µg on aver-
age is used as a contraceptive, however it has not as yet 
been investigated to determine its potential suitability 
for MHT. Barbiturates, phenytoin, products containing 
St. John’s wort, ritonavir, griseofulvin, rifampicin, am-
picillin and other antibiotics weaken the activity of 
levonorgestrel. Levonorgestrel-containing preparations 
may increase the risk of toxic activity of cyclosporine.
Norethisterone and norethisterone acetate
Norethisterone (NET) and norethisterone acetate 
(NETA) are characterized by very similar pharmacoki-
netics and pharmacodynamics. Following oral admin-
istration NETA is rapidly hydrolyzed to NET. Their bio-
availability is 40-80% and depends on molecule size 
and time of taking the drug (it is higher for smaller 
molecules taken in the fasted state) [12]. In the blood, 
NET is bound in 60% to albumins and in 36% to SHBG. 
The half-life is 9.5 hours and 1.5 hours, respectively. 
Around 90% of metabolites retain the ethyl group. One 
of them, 5α-dihydro-NET, has a high relative affinity to 
the AR and is responsible for its weak androgenic activ-
ity. A trace amount of NET (< 0.5%) is aromatized in the 
liver to ethinyloestradiol, which has no clinical relevance 
at a dose of 1 mg, however 5 mg of NET is equivalent 
to the ingestion of 30 µg of EE [13]. Norethisterone 
demonstrates no glucocorticoid or antimineralcorticoid 
activity. After taking a single 0.5 mg dose of NETA the 
maximum concentration of NET in the blood (5 ng/ml) 
is detected after one hour. For the 1 mg dose, it equals 
5-10 ng/ml, and for 2 mg – 12 ng/ml. A combination 
with oestradiol does not alter the pharmacodynamics 
of NET. Multiple repeated doses ensure a stable concen-
tration of ca. 7.4 ng/ml.
The transdermal release of 250 µg of NETA from 
a  patch produces the concentration of 0.5-1.0 ng/ml 
on the second day of application, after which it falls 
to 0.25-0.5 ng/ml. The continuous transdermal applica-
tion of 140 or 250 µg of NETA combined with 50 µg 
of oestradiol provides effective endometrial protection 
from hyperplasia. The frequency of bleeding is lower at 
smaller NETA doses. Similarly, sequential therapy com-
bining the release of 50 µg of oestradiol with a 170 or 
250 µg addition of NETA between the 15th and 28th day 
of the cycle protects the endometrium and causes reg-
ular withdrawal bleeding in 80% of women, irregular 
bleeding in 11% and no bleeding in 9% [14]. Rifampic-
in, some antiepileptic medicines (phenytoin), barbitu-
rates and phenylbutazone accelerate the metabolism 
of norethisterone, thus weakening its progestogenic 
action. 
Cyproterone acetate
Cyproterone acetate (CPA) is bioavailable in nearly 
100% after oral administration. The majority of the drug 
(ca. 93%) remains bound to albumins, without bind-
ing either to SHBG or CBG. It demonstrates the high-
est antiandrogenic activity of all progestins, chiefly as 
a result of competitive inhibition of androgen binding 
to the AR with a dose-dependent potency, and only to 
a minor extent as a consequence of activity exerted by 
the important metabolite 5β-hydroxyCPA. After a single 
2 mg dose CPA achieves the blood serum concentration 
of 11 ng/ml. Cyproterone acetate accumulates in fatty 
tissues, which may lead to secondary disorders of the 
bleeding pattern during prolonged treatment and after 
discontinuation. 
It is used in the therapy of hirsutism, androgenic 
alopecia, and severe and moderate androgen-induced 
acne which is not successfully treated with other an-
tiandrogenic drugs. Cyproterone is metabolized by iso-
enzyme CYP3A4 of cytochrome P450, so its metabolism 
can be inhibited by ketoconazole, itraconazole, clotri-
mazole and ritonavir. On the other hand, CYP 3A4 in-
ducers (e.g. rifampicin, phenytoin, products containing 
St. John’s wort) can increase the metabolism of cypro-
terone, reducing its blood concentration. Cyproterone 
at high doses (300 mg/d) can inhibit isoenzymes CYP 
2C9, 2C19, 3A4 and 2D6 of cytochrome P450, inducing 
the risk of adverse pharmacokinetic interactions with 
diverse clinical features. The concurrent use of statins 
(especially lovastatin, simvastatin and atorvastatin) in-
creases the risk of myopathy or rhabdomyolysis. Con-
sequently, muscle pain experienced by patients taking 
cyproterone acetate and statins should not be ignored.
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Tab. II. Biological activity of progestogens
Progestogen type
Progesto-
genic
Antigon-
adotropic
Antioes-
trogenic
Oestro-
genic
Andro-
genic
Antiandro-
genic
Glucocor-
ticoid
Antimin-
eralocorti-
coid
Progesterone + + + – – +/- + +
Dienogest + + +/– +/– – + – –
Drospirenone + + + – – + – +
Dydrogesterone + – + – – +/– – +/–
Levonorgestrel + + + – + – – –
Norethisterone + + + + + – – –
Cyproterone acetate + + + – – ++ + –
Medroxyprogesterone 
acetate
+ + + – +/– – + –
Nomegestrol acetate + + + – – +/– – –
Designation of activity: (+) effective, (+/–) weak, (–) none.
Medroxyprogesterone acetate
Medroxyprogesterone acetate (MPA) has a  higher 
progestagenic activity and better bioavailability than 
oral progesterone thanks to a slightly different chemi-
cal structure (methyl group at C6 and acetate group at 
C17). Medroxyprogesterone acetate exhibits a relative-
ly high affinity to the PR. It also binds to the androgen 
and glucocorticoid receptors, however without binding 
to the oestrogen and mineralcorticoid receptors.
Following oral administration, it binds weakly to al-
bumins, but without binding to SHBG. In fact, it seems 
to decrease the concentration of SHBH by around 
a dozen percent owing to weak androgenic properties. 
After a  single oral dose of 10 mg, MPA achieves the 
maximum concentration in the blood, in the range of 
3.4-4.4 ng/ml, after 1-4 hours. The concentration falls 
rapidly after 6-12 hours, and equals 0.3-0.6 ng/ml after 
24 hours [15].
The sequential administration of MPA in conjunc-
tion with E
2V has been shown to cause a  1.6-1.8 in-
crease in the AUC (area under the curve) in women over 
65 years of age compared to younger postmenopausal 
women. 
Medroxyprogesterone acetate is used in contracep-
tion (subcutaneous or intramuscular injections of long-
acting forms), in the treatment of excessively heavy or 
prolonged bleeding, for the relief of endometriosis pain 
and in MHT. Menopausal hormone therapy prepara-
tions which are available in Poland contain oestradiol 
valerate. However, there are no classic combinations 
with conjugated oestrogens which were investigated 
in the WHI (Women’s Health Initiative) study, and pre-
viously in HERS I and II (Heart and Estrogen/Progestin 
Replacement Study). Some years ago, high-dose MPA 
therapy was administered in endometrial hyperplasia 
and inoperable endometrial cancer. The concurrent 
use of aminoglutethimide can accelerate the biological 
transformation of medroxyprogesterone and diminish 
Tab. I. Classification of progestogens
1. Progesterone
2. Retroprogesterone (dydrogesterone)
3. Progesterone derivatives
A. 17α-hydroxyprogesterone derivatives (pregnanes)
17α-hydroxyprogesterone caproate
17α-hydroxyprogesterone heptanoate
Chlormadinone acetate
Cyproterone acetate
Medroxyprogesterone acetate
B. 19-norprogesterone derivatives (norpregnanes)
Nomegestrol acetate
Demegestone
Promegestone
Trimegestone
Nesterone
4. Testosterone derivatives
A. 19-nortestosterone derivatives (estranes)
Lynestrenole
Norethynodrel
Norethisterone/norethisterone acetate
Ethynodiol diacetate
Norgestrinone
Dienogest
B. 19-nortestosterone derivatives (13-ethylgonanes)
Levonorgestrel / norgestrel
Desogestrel / etonogestrel (active metabolite)
Gestodene
Norgestimate/norelgestromin (active metabolite)
5. Spironolactone derivatives
Drospirenone
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its efficacy. The drug can also interfere with metyrapone 
test results.
Nomegestrol acetate
Nomegestrol acetate (NOMAC) is a  derivative of 
19-norprogesterone. It achieves its maximum blood 
concentration within 2-3 hours after oral administra-
tion irrespective of the dose, and has a half-life of 50 
hours. The bioavailability of the drug is 65%. NOMAC 
is metabolized in the liver, mainly in the CYP3A4 and 
CYP3A5 systems, which is why it can enter into clini-
cally significant interactions under the influence of 
ketoconazole, rifampicin and certain anticonvulsant 
drugs. Anticonvulsants (carbamazepine, phenobarbital, 
phenytoin, primidone), barbiturates, griseofulvin, ri-
fabutin and rifampicin can decrease the efficacy of no-
megestrol [16, 17]. Stable concentrations are achieved 
after five days of treatment. Impaired liver function can 
result in the accumulation of the drug. The majority of 
the drug binds to albumins, without binding to SHBG 
and CBG [18]. It is a  very potent PR agonist. It dem-
onstrates a weak antioestrogenic action, and does not 
bind to the AR, GR or MR.
Nomegestrol acetate is used at daily doses ranging 
from 2.5 to 10 mg in the management of menstrual dis-
orders. 
Due to its potent antigonadotropic action, no-
megestrol acetate is used in COCP at a dose of 2.5 mg 
in conjunction with oestradiol (1.5 mg) in the regimen 
of 24 active tablets plus 4 placebo tablets.
In MHT applications, studies were conducted on 
regimens combining NOMAC at doses of 1.5-5 mg with 
oestradiol at doses of 1.0-2.5 mg. The studies dem-
onstrated the elimination of menopausal symptoms 
accompanied by a  concurrent favourable effect on 
blood lipids, but an increase in the concentration of an-
tithrombin III.
Nomegestrol acetate is used in sequential therapy 
at a dose of 5 mg for 12-14 days of the cycle, and in 
continuous therapy at 2.5-3.75-5 mg daily. 
Clinical activities of progestogens in 
menopausal hormone therapy
Effect on the endometrium
The main and essential activity exerted by progesto-
gen is the transformation of the endometrium from its 
proliferative into secretory form, and hence endometri-
al protection from hyperplasia and cancer. The antipro-
liferative action stems from the inhibition of oestrogen-
induced mitotic activity, ER reduction, increased activity 
of enzymes (17β-hydroxysteroid dehydrogenase type 2 
converting oestradiol into oestrone, and sulphotrans-
ferase leading to the formation of oestrone sulphate), 
which results in oestrogen elimination from the body 
and IGFBP-1 stimulation inhibiting the mitogenic effect 
of the IGF on the endometrium.
The optimum daily progestogen dose should inhibit 
mitotic activity within a short period (≤ 2 mitoses/1,000 
glandular cells at the end of a  single course of treat-
ment), and should not induce endometrial hyperplasia 
over a long period (≤ 2 cases of hyperplasia/100 wom-
en/12 months). In addition to the dose, a  significant 
factor is also the duration of use (at least 10 days in 
cyclic treatment and 12 days in sequential therapy). 
The best endometrial protection is achieved with 
the continuous therapeutic regimen. Table III lists oral 
progestogen doses used in MHT.
Effect on the mammary glands
A recent publication presenting results obtained in 
the 13-year follow-up of women who took part in the 
Women’s Health Initiative (WHI) study demonstrated 
that the total relative risk (RR) of breast cancer was 
1.28 (1.11-1.48) in oestrogen/progestogen therapy, and 
0.79 (0.65-0.97) in oestrogen monotherapy. The values 
were statistically significant in both cases, suggest-
ing that the increase or decrease in the risk of breast 
cancer was crucially dependent on the presence of pro-
gestogen (in this case medroxyprogesterone acetate) 
[20]. Nevertheless, interpretations of the results are 
very cautious both in terms of risk (< 1 breast cancer 
case per 1,000 women more in the group receiving oes-
trogen/progestogen therapy) and protection (< 1 breast 
cancer case per 1,000 women less in the oestrogen 
therapy group). Commentators draw attention to the 
possibility of systematic errors, including the bias of 
detection or monitoring, which may eliminate any un-
Tab. III. Daily oral progestogen dose ensuring endometrial 
protection in MHT [19]
Progestogen Daily dose (mg)
Therapy
Sequential
Continuous
Progesterone 200-300 100
Dienogest 3-4 –
Drospirenone – 2
Dydrogesterone 10-20 2.5-10
Levonorgestrel 0.075-0.15 –
Cyproterone acetate 1 –
Medroxyprogesterone acetate 5-10 2.5
Nomegestrol acetate 5-10 2.5
Norethisterone acetate 1-2 0.5-1.0
(–) symbol – not determined.
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favourable or favourable effect of therapy [21]. How-
ever, results of other epidemiological studies published 
after 2000 indicate consistently that adding progestin 
to oestrogen contributes to an increase in breast cancer 
risk compared to oestrogen monotherapy. For example, 
a study of a population of 33,000 women aged 50 to 64 
years showed that the risk of breast cancer in users of 
oestrogens alone was OR = 0.96 (0.88-1.06), but in us-
ers of conjugated E + P it rose to OR = 1.44 (1.31-1.58) 
[22]. Similar outcomes were recorded in a cohort study 
of 67,754 women. In the group using E + P therapy, 
there was an increased risk of ductal cancer – RR = 1.75 
(1.59-2.01) and lobular breast cancer – RR = 2.12 (1.62-
2.77), whereas in the group taking oestrogens only 
(CEE) the values were: RR = 0.99 (0.84-1.17) for ductal 
cancer and RR = 1.13 (0.94-1.78) for lobular breast can-
cer [23]. Important findings were also reported in the 
French E3 Cohort Study, indicating that not all progesto-
gens act in the same way, and that the outcomes of 
the WHI study should not be extrapolated to other MHT 
types and regimens [24]. In a group of 80,377 postmen-
opausal women, of which 70% used MHT for an aver-
age of 7 years and were followed up for 8 years, there 
were 2,354 cases of breast cancer. No statistically sig-
nificant increase in the risk of breast cancer was found 
among women using transdermal oestrogens alone 
and oestrogens in conjunction with progesterone or 
dydrogesterone during up to 5 years of therapy. In con-
trast, a statistically significant increase in breast cancer 
risk was determined for other E + P therapy regimens 
containing seven other progestogens: chlormadinone 
acetate, cyproterone acetate, medroxyprogesterone 
acetate, nomegestrol acetate, norethisterone acetate, 
promegestone or medrogestone. The route of oestro-
gen administration was also shown to be a potentially 
important factor.
The highest proliferative activity in normal breast 
tissue in the physiological cycle is observed in the lu-
teal phase. Experimental in vitro studies aim to evalu-
ate the effect of different progestogens on apoptosis/
proliferation indices in healthy tissue cell lines and in 
breast cancer. Unfortunately, different progestogens are 
rarely investigated using the same model of experimen-
tal conditions and breast cell lines. 
Effect on the cardiovascular system
Evaluation of the impact of MHT on the risk of car-
diovascular diseases takes into account effects on the 
composition of blood lipids, arterial function, vascular 
inflammatory markers, changes in the blood coagula-
tion system and carbohydrate metabolism. 
The WHI study concerning both the entire investi-
gated group of women and detailed analyses of therapy 
in consecutive decades of life point to major differences 
between the oestrogen arm (CEE) and the oestrogen/
progestogen arm (CEE + MPA) in favour of the former. 
An example is the frequency of cardiac episodes re-
ported among women in the age group of 50-59 years. 
In the group receiving oestrogen therapy the risk was 
lower (HR = 0.63 (0.36-1.09)) than in the group of E + P 
therapy (HR = 1.29 (0.79-2.12)) [25]. Similar differences 
were noted for the risk of venous thromboembolism. 
Combined E + P therapy caused a significant increase 
in the risk of thromboembolic complications: HR = 2.06 
(1.57-2.70), whereas in the oestrogen arm only a grow-
ing trend was noted: HR = 1.33 (0.86-2.08) [26]. A ques-
tion arises as to the degree to which the findings are 
attributable to medroxyprogesterone acetate and the 
role of other factors, e.g. different characteristics of the 
compared women’s cohorts.
An adverse effect of MPA was already noted in the 
first randomized clinical trial of MHT: Postmenopausal 
Estrogen/Progestin Intervention (PEPI). A  significantly 
higher rise in HDL cholesterol concentration was only 
noted in the group which received P. In macaque stud-
ies, CEE + MPA increased fasting glucose and insulin 
levels, and led to worse glucose challenge test results 
than in the group which only received CEE.
A  positive effect on the blood lipids is noted for 
progesterone and progestins – 19-norprogesterone de-
rivatives, as opposed to a  negative effect induced by 
19-nortestosterone and MPA.
A  metaanalysis of 248 studies published in 1974-
2000, encompassing 42 different MHT regimens, ena-
bled an assessment of progestogens focusing on their 
impact on the lipid profile [27]. In general terms, pro-
gesterones modified the oestrogen-induced fall in total 
and LDL cholesterol levels only to a minor degree, and 
as a rule had no impact on the adverse rise in triglyc-
erides triggered by oral oestrogen intake. Based on the 
elimination of the beneficial rise in HDL cholesterol con-
centration, they can be ranked as follows: dydrogester-
one and medrogestone – the lowest effect, followed by 
progesterone, CPA, MPA, transdermal NETA, LNG and 
oral NETA.
C-reactive protein (CRP) is recognized as a marker 
of chronic arteritis which is linked to the risk of coro-
nary heart disease, ischaemic stroke and vascular mor-
tality. The importance of different oestrogen effect on 
the CRP value depending on the route of administration 
and dose is debatable. Progestins which demonstrate 
a certain level of androgenic activity are able to influ-
ence the concentration of CRP, lipid profile and glucose 
tolerance. An addition of progesterone or dydrogester-
one to oestrogen does not negatively affect the CRP 
concentration [28].
In the group of progestogens, drospirenone is dis-
tinct for its statistically significant effect on the de-
crease in morning systolic blood pressure caused by its 
antimineralcorticoid properties [29]. A beneficial effect 
on 24-h ambulatory arterial blood pressure measure-
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ments in healthy women is achieved through the com-
bination of a low dose (1 mg) of oestradiol with dydro-
gesterone [30].
Progesterone and some pregnanes, devoid of an-
drogenic activity, seem to have a  beneficial effect on 
the parameters of the coagulation system. The ob-
servation was corroborated in the prospective cohort 
study E3N (Etude Epidémiologique de l’Education Na-
tionale) which analyzed a  total of 549 cases of first 
venous thromboembolism in a  group of 80,308 post-
menopausal women [31]. Neither progesterone nor 
pregnanes such as dydrogesterone and chlormadinone 
acetate were found to affect the risk of venous throm-
boembolism. Norpregnanes (nomegestrol acetate and 
promegestone) led to a significant increase in the risk 
of venous complications: OR = 1.8 (1.2-2.7).
A metaanalysis of studies addressing the effects of 
MHT on the metabolic syndrome showed MHT to re-
duce insulin resistance in healthy and diabetic women 
[32]. Dydrogesterone does not cancel out the favour-
able impact of oestradiol on fasting glucose and insulin 
concentrations, and even halts the menopause-related 
trend for disorders of insulin secretion [33].
Effects on bones
The majority of progestogens do not interfere with 
the favourable activity of oestrogens in the prevention 
and treatment of osteoporosis. 
Only norethisterone acetate in high doses, which 
are unacceptable nowadays due to their adverse vascu-
lar effects, would be capable of preventing postmeno-
pausal bone resorption alone [34].
Effects on the brain
Progesterone is an important neurosteroid which is 
synthesized de novo in the brain, spinal cord and pe-
ripheral nerves. In clinical trials it exhibits neuroprotec-
tive properties after brain injury [35]. 
Widely known experimental studies conducted by 
Catherine Woolley and Elizabeth Gould showed pro-
gesterone to inhibit, within a period of 12 hours, the 
process of oestradiol-induced synapse formation in the 
rat hippocampus. The effect occurs even though the 
presence of the classic PR was not identified, however 
its expression was detected in extranuclear neuronal 
sites [36].
In turn, cultures of rat hippocampus neurons, in 
which progesterone and 19-norprogesterone had 
a protective activity, showed that MPA exerted an op-
posite effect, eliminating the positive effects produced 
by oestradiol. Medroxyprogesterone acetate also an-
tagonizes the restoration of mitochondrial function 
provoked by oestradiol and progesterone in ovariecto-
mized rat females [37]. There is, as yet, no basis for gen-
eralizing conclusions arising from scarce experimental 
studies. 
Conclusions
For many decades, the role of progesterone in MHT 
was limited to endometrial protection. There is an in-
creasing body of data coming both from experimental 
studies and clinical trials, suggesting not only that there 
are significant dissimilarities between different pro-
gestogens, but also that they can variously modify the 
actions induced by oestrogens. Gaining greater insights 
into their role should make it possible to consciously 
adjust progestogen use during MHT.
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